Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
Aims to become India’s leading cancer testing company
Reaffirms Lupin’s commitment to sustainable resource management
Subscribe To Our Newsletter & Stay Updated